E-resources
Peer reviewed
-
Chen, Nan; Saha, Poornima; Rampurwala, Murtuza M.; Kamaraju, Sailaja; Hahn, Olwen Mary; Howard, Frederick Matthew; Fleming, Gini F.; Matossian, Margarite; Freeman, Jincong Q.; Karrison, Theodore; Conzen, Suzanne D.; Nanda, Rita; Stringer-Reasor, Erica Michelle
Journal of clinical oncology, 06/2023, Volume: 41, Issue: 16_supplJournal Article
e13103 Background: Despite recent advances, treatment (tx) of metastatic triple-negative breast cancer (TNBC) remains an important unmet clinical need. Activation of the glucocorticoid receptor (GR) initiates cell survival pathways, leading to chemotherapy resistance. Furthermore, high GR expression is a negative prognostic marker in early-stage, hormone receptor negative breast cancer. We hypothesized that GR antagonism with mifepristone (mif) prior to the administration of cytotoxic chemotherapy would improve efficacy by blocking the potent anti-apoptotic signals mediated by GR activation. Methods: We conducted a phase II, randomized, placebo-controlled, multi-center study of nab-paclitaxel (nab-pac) with or without mif in patients (pts) with locally advanced, unresectable or metastatic TNBC (NCT02788981). Prior tx with nab-pac was not allowed. Two prior chemotherapies allowed in the metastatic setting. Pts were randomized to receive nab-pac 100mg/m 2 on day 1, 8, and 15 of a 28-day cycle with mif 300mg or placebo the day prior and day of each dose of nab-pac. The primary endpoint was progression free survival (PFS). Secondary endpoints included objective response rate (ORR), overall survival (OS), and safety and tolerability. Results: 29 patients were enrolled from September 2017 to July 2021; 16 patients were randomized to nab-pac+placebo and 13 patients to nab-pac+mif. The mean age was 53 years (range 32-73) and 34% of pts were self-reported Black. The median PFS was 3.0 and 3.0 months (mos) in the nab-pac alone and combination arms respectively (hazard ratio HR 0.87, 95% CI 0.37 – 2.01, p=0.739. ORR in the nab-pac and combination arms were 31.5% and 23%, respectively; both arms had 1 complete response (CR). Median OS with nab-pac alone was 6.0 mos and in the combination arm was 9.0 mos (HR=0.67, 95% CI 0.29 – 1.16, p=0.350. The pt on the mif arm who achieved a CR completed 50 cycles and ultimately died of a non-cancer, non-tx related event. Tx was generally well-tolerated, with a safety profile comparable with nab-pac monotherapy. The most common treatment-related adverse events (TRAEs) were fatigue (50%), neuropathy (42%), and neutropenia (42%); the most common grade 3 TRAE was neutropenia. Grade 3 neutropenia occurred more frequently in pts receiving nab-pac+mif (69% vs 13%). Conclusions: This study did not achieve the desired statistical power due to poor accrual attributed to the COVID-19 pandemic and the approval of checkpoint inhibitors in advanced TNBC. Nonetheless, in this subset of patients, the addition of mif to nab-pac did not significantly improve PFS compared to nab-pac alone. There was a trend towards improvement in OS, primarily driven by one long-term responder. GR activation remains relevant in advanced TNBC. Further investigation of this pathway and other strategies to target chemotherapy resistance are needed. Clinical trial information: NCT02788981 .
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.